A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities

Autor:	Liangyin Lv, Hui Wang, Wenqiang Shi, Yang Wang, Wen Zhu, Zexin Liu, Xiaoqu Chen, Chen Zheng, Wencheng Kong, Wei Li, Jianwei Zhu, Huili Lu
Rok vydání:	2022
Předmět:	Interleukin-15 Biological Products Programmed Cell Death 1 Receptor Angiogenesis Inhibitors Antineoplastic Agents General Medicine CD8-Positive T-Lymphocytes Applied Microbiology and Biotechnology B7-H1 Antigen Immunoglobulin Fc Fragments Bevacizumab Mice Cell Line Tumor Immunoglobulin G Animals Humans Immunotherapy Immune Checkpoint Inhibitors Half-Life Biotechnology
Zdroj:	Applied Microbiology and Biotechnology. 106:7039-7050
ISSN:	1432-0614 0175-7598
DOI:	10.1007/s00253-022-12209-1
Popis:	Interleukin-15 (IL-15) is a promising candidate for cancer immunotherapy due to its potent immune-activating effects. There are several IL-15 molecules currently in clinical trials but facing shortages of poor half-life, circulation instability, or complicated production and quality control processes. The aim of this study is to design a novel IL-15 superagonist to set out the above difficulties, and we constructed F4RLI consisting of the GS-linker spaced IgG4 Fc fragment, soluble IL-15 Rα (sIL-15Rα), and IL-15(N72D). Using a single plasmid transient transfection in HEK293E cells, the matured F4RLI was secreted in the form of homodimer and got purified by an easy step of protein A affinity chromatography. The F4RLI product can significantly stimulate the proliferation of human CD3
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87d8b4205dc48f1ac2aa5c8678b17f9 https://doi.org/10.1007/s00253-022-12209-1 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.